Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 19
HOS-086286 · Präparat HOS-083284
Calcium channel antagonists
Amlodipine, diltiazem, nifedipine Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of
calcium channel antagonists. Careful monitoring of therapeutic and adverse effects
is recommended when these medicines are concomitantly administered with
ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) amlodipine (HOS-086287) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 06a8c4c596fcc9657c0c6cc40e076c83360ca96e86778c1ba3f84a1fe828550d · Zeichen 39955–40494 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51
HOS-086463 · Präparat HOS-083284
Calcium channel antagonists
Amlodipine, diltiazem, nifedipine Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits
CYP3A4 and as a result is expected to increase the plasma concentrations of calcium
channel antagonists. Careful monitoring of therapeutic and adverse effects is
recommended when these medicines are concomitantly administered with ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nifedipine (HOS-086289) amlodipine (HOS-086287) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ebee11840446abd8efc918d28a6d805600eb471e8292bbf255860ff8f3f839d1 · Zeichen 41018–41536 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 9
HOS-090599 · Präparat HOS-084095
Diltiazem (CYP3A4 inhibitor)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 319f165c84f7152e49144dd8cc54e3dc9cd4751857bb244d921b58bbe6d85b6d · Zeichen 2023–2051 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 9
HOS-090600 · Präparat HOS-084095
The simultaneous oral administration of 10 mg of Rapamune oral solution and 120 mg of diltiazem
significantly affected the bioavailability of sirolimus. Sirolimus Cmax, tmax, and AUC were increased
1.4-fold, 1.3-fold, and 1.6-fold, respectively. Sirolimus did not affect the pharmacokinetics of either
diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem. If diltiazem is administered,
sirolimus blood levels should be monitored and a dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage db8b7c069096aa259d7e0cea2dff9a073ca975953bea4d82e5e9c04eafe41193 · Zeichen 2053–2539 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090671 · Präparat HOS-084095
Diltiazem (CYP3A4 inhibitor)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 319f165c84f7152e49144dd8cc54e3dc9cd4751857bb244d921b58bbe6d85b6d · Zeichen 1966–1994 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090672 · Präparat HOS-084095
The simultaneous oral administration of 10 mg of Rapamune oral solution and 120 mg of diltiazem
significantly affected the bioavailability of sirolimus. Sirolimus Cmax, tmax, and AUC were increased
1.4-fold, 1.3-fold, and 1.6-fold, respectively. Sirolimus did not affect the pharmacokinetics of either
diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem. If diltiazem is administered,
sirolimus blood levels should be monitored and a dose adjustment may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage db8b7c069096aa259d7e0cea2dff9a073ca975953bea4d82e5e9c04eafe41193 · Zeichen 1996–2482 im Abschnitt
Wechselwirkungen · Protopic
Protopic 0.03% ointment · Abschnitt 4.5 · PDF-Seite 5
HOS-109232 · Präparat HOS-093151
Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4).
Systemic exposure from topical application of tacrolimus ointment is low (<1.0 ng/ml) and is unlikely
to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the
possibility of interactions cannot be ruled out and the concomitant systemic administration of known
CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with
widespread and/or erythrodermic disease should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T12:15:00Z · SHA-256 5825006b3b9f5f6765fd606bf2f8808250e5df6121179a915de3a36fc9e9b9e4 · Passage 8a824b296c7b74170b7137e2fa5b4579f58193231aaeb951239988c5b7be0106 · Zeichen 253–811 im Abschnitt
Wechselwirkungen · Protopic
Protopic 0.1% ointment · Abschnitt 4.5 · PDF-Seite 17
HOS-109246 · Präparat HOS-093151
Systemically available tacrolimus is metabolised via the hepatic Cytochrome P450 3A4 (CYP3A4).
Systemic exposure from topical application of tacrolimus ointment is low (< 1.0 ng/ml) and is unlikely
to be affected by concomitant use of substances known to be inhibitors of CYP3A4. However, the
possibility of interactions cannot be ruled out and the concomitant systemic administration of known
CYP3A4 inhibitors (e.g. erythromycin, itraconazole, ketoconazole and diltiazem) in patients with
widespread and/or erythrodermic disease should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoconazole (HOS-084513) itraconazole (HOS-084516) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T12:15:00Z · SHA-256 5825006b3b9f5f6765fd606bf2f8808250e5df6121179a915de3a36fc9e9b9e4 · Passage 3484056429fcfa04e5e69d58fac15375732ed184c20de1fe109b7c1574fe203c · Zeichen 253–812 im Abschnitt
Wechselwirkungen · Abilify
ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-217754 · Präparat HOS-216111
7
ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh
the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole
occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other
strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to
have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased
to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g.
diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases
in plasma aripiprazole concentrations may be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:00:00Z · SHA-256 48ec4699460ea38cacf1c891061adc75be0cb67e5657869eb4f756b4f121c005 · Passage 99af5825d02c08ae997d49ebb7f342ec9659694e399749aac05caf2f7a3d4bb2 · Zeichen 2112–2970 im Abschnitt
Wechselwirkungen · Abilify
ABILIFY 10 mg orodispersible tablets ABILIFY 15 mg orodispersible tablets ABILIFY 30 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-217814 · Präparat HOS-216111
Ketoconazole and other CYP3A4 inhibitors
In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased
aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-
aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant
use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole
compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of
ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh
the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole
occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other
strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to
have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased
to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g.
diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases
in plasma aripiprazole concentrations may be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:00:00Z · SHA-256 48ec4699460ea38cacf1c891061adc75be0cb67e5657869eb4f756b4f121c005 · Passage f16aac854a00d18bce77e3d8d405963713c946ce9ea25743b4ba785b7c99bab0 · Zeichen 1605–2971 im Abschnitt
Wechselwirkungen · Abilify
ABILIFY 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 47
HOS-217857 · Präparat HOS-216111
Ketoconazole and other CYP3A4 inhibitors
In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased
aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-
aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant
use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole
compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of
ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh
the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole
occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other
strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to
have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased
to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g.
diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases
in plasma aripiprazole concentrations may be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:00:00Z · SHA-256 48ec4699460ea38cacf1c891061adc75be0cb67e5657869eb4f756b4f121c005 · Passage f16aac854a00d18bce77e3d8d405963713c946ce9ea25743b4ba785b7c99bab0 · Zeichen 1548–2914 im Abschnitt
Wechselwirkungen · Abilify
ABILIFY 7.5 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 66
HOS-217904 · Präparat HOS-216111
Ketoconazole and other CYP3A4 inhibitors
In a clinical trial of oral aripiprazole in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole)
increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively. The AUC and Cmax of dehydro-
aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant
use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole
compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of
ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh
the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole
occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other
strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to
have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon
discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased
to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g.
diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases
in plasma aripiprazole concentrations may be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) protease (HOS-085623) ketoconazole (HOS-084513) itraconazole (HOS-084516) escitalopram (HOS-129417)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:00:00Z · SHA-256 48ec4699460ea38cacf1c891061adc75be0cb67e5657869eb4f756b4f121c005 · Passage d997dcbb47b7ac47c99974cc7196e9e27c11f373ff8a4d172df0119bfd3a9dae · Zeichen 2237–3624 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 19–20
HOS-112103 · Präparat HOS-093615
19
Medicinal products by Interaction Recommendations concerning co-
therapeutic area administration
Calcium channel blockers
Bepridil REYATAZ should not be used in Co-administration with bepridil is
combination with medicinal products that contraindicated (see section 4.3)
are substrates of CYP3A4 and have a
narrow therapeutic index.
Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of
(atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is recommended,
Diltiazem Cmin: ↑142% (↑114% ↑173%) with subsequent titration as needed
and ECG monitoring.
Desacetyl-diltiazem AUC: ↑165% (↑145%
↑187%)
Desacetyl-diltiazem Cmax: ↑172% (↑144%
↑203%)
Desacetyl-diltiazem Cmin: ↑121% (↑102%
↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) bepridil (HOS-085612) calcium (HOS-085615)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage a5938ef1523f856eb59b74422c7cfaea01c48399a19f2b7a8ea958d4d8e50ef3 · Zeichen 51161–52517 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 20
HOS-112104 · Präparat HOS-093615
No significant effect on atazanavir
concentrations was observed. There was an
increase in the maximum PR interval
compared to atazanavir alone. Co-
administration of diltiazem and
REYATAZ/ritonavir has not been studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage e07acb573055757be7e62809a0891f8a26b2a21d01c50b1747bd9a48b0cb41dd · Zeichen 52552–52936 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 20
HOS-112105 · Präparat HOS-093615
The mechanism of diltiazem/atazanavir
interaction is CYP3A4 inhibition.
Verapamil Serum concentrations of verapamil may be Caution should be exercised when
increased by REYATAZ due to CYP3A4 verapamil is co-administered with
inhibition. REYATAZ.
CORTICOSTEROIDS
Dexamethasone and other Co-administration with dexamethasone or Co-administration with
corticosteroids (all routes of other corticosteroids that induce CYP3A corticosteroids (all routes of
administration) may result in loss of therapeutic effect of administration) that are metabolised
REYATAZ and development of resistance by CYP3A, particularly for
to atazanavir and/or ritonavir. Alternative long-term use, may increase the risk
corticosteroids should be considered. for development of systemic
corticosteroid effects including
The mechanism of interaction is CYP3A4 Cushing’s syndrome and adrenal
induction by dexamethasone and CYP3A4 suppression. The potential benefit
inhibition by atazanavir and/or ritonavir. of treatment versus the risk of
systemic corticosteroid effects
should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) dexamethasone (HOS-084535) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 77c2a7b825f8edae519f369c3cf8eeda90f40c9d448e7520b3ddf838e16d5e74 · Zeichen 52971–54720 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 54–55
HOS-112192 · Präparat HOS-093615
54
Medicinal products by Interaction Recommendations
therapeutic area concerning co-administration
Ivosidenib The mechanism of interaction is CYP3A4 Co-administration of
inhibition by atazanavir and/or ritonavir. ivosidenib with REYATAZ
(with or without ritonavir) is
contraindicated due to potential
for loss of virologic response,
development of resistance,
increase in ivosidenib plasma
concentration and subsequent
risk of serious adverse events
such as QT interval
prolongation (see section 4.3).
Irinotecan Atazanavir inhibits UGT and may interfere If REYATAZ is co-
with the metabolism of irinotecan, resulting administered with irinotecan,
in increased irinotecan toxicities. patients should be closely
monitored for adverse events
related to irinotecan.
Immunosuppressants
Cyclosporin Concentrations of these More frequent therapeutic
Tacrolimus immunosuppressants may be increased concentration monitoring of
Sirolimus when co-administered with REYATAZ due these medicinal products is
to CYP3A4 inhibition. recommended until plasma
levels have been stabilised.
CARDIOVASCULAR AGENTS
Antiarrhythmics
Amiodarone, Concentrations of these antiarrhythmics Caution is warranted and
Systemic lidocaine, may be increased when co-administered therapeutic concentration
Quinidine with REYATAZ. The mechanism of monitoring is recommended
amiodarone or systemic when available. The
lidocaine/atazanavir interaction is CYP3A concomitant use of quinidine is
inhibition. Quinidine has a narrow contraindicated (see
therapeutic window and is contraindicated section 4.3).
due to potential inhibition of CYP3A by
REYATAZ.
Calcium channel blockers
Bepridil REYATAZ should not be used in Co-administration with
combination with medicinal products that bepridil is contraindicated (see
are substrates of CYP3A4 and have a section 4.3)
narrow therapeutic index.
Diltiazem 180 mg once daily Diltiazem AUC: ↑125% (↑109% ↑141%) An initial dose reduction of
(atazanavir 400 mg once daily) Diltiazem Cmax: ↑98% (↑78% ↑119%) diltiazem by 50% is
Diltiazem Cmin: ↑142% (↑114% ↑173%) recommended, with subsequent
titration as needed and ECG
Desacetyl-diltiazem AUC: ↑165% (↑145% monitoring.
↑187%)
Desacetyl-diltiazem Cmax: ↑172% (↑144%
↑203%)
Desacetyl-diltiazem Cmin: ↑121% (↑102%
↑142%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) calcium (HOS-085615) tacrolimus (HOS-085202) ivosidenib (HOS-112046) sirolimus (HOS-085172) ritonavir (HOS-084521) amiodarone (HOS-085596) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8e30f6119b7915e33c652e423a799b6a4590263851081846f12e942eec018b80 · Zeichen 49648–54131 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 55
HOS-112193 · Präparat HOS-093615
No significant effect on atazanavir
concentrations was observed. There was an
increase in the maximum PR interval
compared to atazanavir alone. Co-
administration of diltiazem and
REYATAZ/ritonavir has not been studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage a4f65e65049177479f3cf0dd7bd0794c51a8c44198a16ee51a97555c914e7eda · Zeichen 54165–54544 im Abschnitt
Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 55
HOS-112194 · Präparat HOS-093615
The mechanism of diltiazem/atazanavir
interaction is CYP3A4 inhibition.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 36b8fe691e4e73f67dedf9d7e9861cdbf0778f8c10ed769c1f2d81be046b354f · Zeichen 54578–54681 im Abschnitt
Gegenanzeigen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-113843 · Präparat HOS-093985
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Resting heart rate below 70 beats per minute prior to treatment
- Cardiogenic shock
- Acute myocardial infarction
- Severe hypotension (< 90/50 mmHg)
- Severe hepatic insufficiency
- Sick sinus syndrome
- Sino-atrial block
- Unstable or acute heart failure
- Pacemaker dependent (heart rate imposed exclusively by the pacemaker)
- Unstable angina
- AV-block of 3rd degree
- Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals
(ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin per os,
josamycin, telithromycin), HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see
sections 4.5 and 5.2)
- Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart
rate reducing properties (see section 4.5)
- Pregnancy, lactation and women of childbearing potential not using appropriate contraceptive
measures (see section 4.6)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 038375aab2cfa48edaa49949d6504dd4b3dd7e1bb3de22461a40ede8afbd9e21 · Zeichen 0–1101 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113858 · Präparat HOS-093985
Moderate CYP3A4 inhibitors
Specific interaction studies in healthy volunteers and patients have shown that the combination of
ivabradine with the heart rate reducing agents diltiazem or verapamil resulted in an increase in
ivabradine exposure (2 to 3 fold increase in AUC) and an additional heart rate reduction of 5 bpm. The
concomitant use of ivabradine with these medicinal products is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 30858d59c0de8add857d26fa03aa01561d3e6069fb00377c2e84e11f8c2bb499 · Zeichen 2355–2778 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.